ArticleAnnals of clinical and translational neurology2026
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4-IgG-Positive NMOSD.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveRituximab (anti-CD20, RTX) and inebilizumab (anti-CD19, INE) represent B-cell-depleting therapies used for aquaporin-4 antibody-positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited. This study aimed to evaluate the real-world comparative effectiveness and safety of RTX versus INE.
designThis was a retrospective, multicenter, observational study.
methodsIn this retrospective cohort study, 103 patients with AQP4-IgG+ NMOSD were included, of whom 40 received INE and 63 received RTX. Overlap weighting based on propensity scores was employed to balance baseline covariates, achieving excellent balance (all standardized mean differences < 0.001). The primary outcomes included annualized relapse rate (ARR) and relapse risk, which were analyzed using weighted Poisson regression and Anderson-Gill mode.
resultsAfter weighting, the proportion of patients experiencing any relapse was lower in the INE group than in the RTX group (10.6% vs. 43.9%, p = 0.047). In models accounting for differences in follow-up duration, INE was also associated with a lower post-treatment relapse risk than RTX. Although the restricted mean survival time difference at 27 months favored INE, the difference was not statistically significant. Disability progression was similar between groups, though hypogammaglobulinemia, particularly reduced IgG levels, was more frequently observed with INE (54.1% vs. 17.2%; p < 0.001).
conclusionsIn this real-world cohort, INE showed a trend toward lower relapse risk compared to RTX, whereas demonstrating a manageable safety profile with increased incidence of hypogammaglobulinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.